187 related articles for article (PubMed ID: 24147041)
1. Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier.
Langford-Smith KJ; Sandiford Z; Langford-Smith A; Wilkinson FL; Jones SA; Wraith JE; Wynn RF; Bigger BW
PLoS One; 2013; 8(10):e77632. PubMed ID: 24147041
[TBL] [Abstract][Full Text] [Related]
2. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
4. Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
Shahin K; Mattar Z; Silveira P; Hsu WH; Bendall L; Hart D; Bradstock KF
Transplantation; 2017 Nov; 101(11):2695-2704. PubMed ID: 28319565
[TBL] [Abstract][Full Text] [Related]
5. Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation.
Garcia-Perez L; van Roon L; Schilham MW; Lankester AC; Pike-Overzet K; Staal FJT
Cells; 2021 Apr; 10(5):. PubMed ID: 33946560
[TBL] [Abstract][Full Text] [Related]
6. Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumours.
Youshani AS; Rowlston S; O'Leary C; Forte G; Parker H; Liao A; Telfer B; Williams K; Kamaly-Asl ID; Bigger BW
J Neuroinflammation; 2019 Feb; 16(1):25. PubMed ID: 30722781
[TBL] [Abstract][Full Text] [Related]
7. Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Alvarez M; Pierini A; Simonetta F; Baker J; Maas-Bauer K; Hirai T; Negrin RS
Front Immunol; 2020; 11():614250. PubMed ID: 33488624
[TBL] [Abstract][Full Text] [Related]
8. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
[TBL] [Abstract][Full Text] [Related]
9. Busulfan as a myelosuppressive agent for generating stable high-level bone marrow chimerism in mice.
Peake K; Manning J; Lewis CA; Barr C; Rossi F; Krieger C
J Vis Exp; 2015 Apr; (98):e52553. PubMed ID: 25867947
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
[TBL] [Abstract][Full Text] [Related]
11. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs.
Down JD; Ploemacher RE
Exp Hematol; 1993 Jul; 21(7):913-21. PubMed ID: 8100536
[TBL] [Abstract][Full Text] [Related]
12. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
[TBL] [Abstract][Full Text] [Related]
13. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA
Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic cell transplantation for the induction of allo- and xenotolerance.
Sykes M
Clin Transplant; 1996 Aug; 10(4):357-63. PubMed ID: 8884109
[TBL] [Abstract][Full Text] [Related]
15. Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.
Hu M; Kramer B; Zhang GY; Wang YM; Watson D; Howden B; McCowage G; Alexander IE; Gunning P; Alexander SI
Transplantation; 2015 Dec; 99(12):2476-84. PubMed ID: 26177088
[TBL] [Abstract][Full Text] [Related]
16. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
17. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
18. Maternal Administration of Busulfan before in Utero Hematopoietic Cell Transplantation Improves Congenic Bone Marrow Cell Engraftment in a Murine Model.
Shi C; Li Z; Sun Z; Pan L
Transplant Cell Ther; 2024 Apr; 30(4):398.e1-398.e10. PubMed ID: 38331194
[TBL] [Abstract][Full Text] [Related]
19. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Uchida N; Matsumoto K; Sakura T; Hidaka M; Miyamoto T; Eto T; Maeda Y; Murayama T; Fujishima N; Yoshimoto G; Morita K; Kishimoto J; Teshima T; Taniguchi S; Yamashita T; Mori SI; Akashi K; Harada M;
Int J Hematol; 2020 Oct; 112(4):510-523. PubMed ID: 32656637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
